Plato Investment Management Ltd Acquires New Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Plato Investment Management Ltd bought a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 423 shares of the medical research company’s stock, valued at approximately $139,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Bio-Rad Laboratories by 1.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock worth $147,583,000 after purchasing an additional 4,260 shares during the last quarter. Westfield Capital Management Co. LP increased its holdings in shares of Bio-Rad Laboratories by 3.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock worth $84,571,000 after buying an additional 9,584 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Bio-Rad Laboratories during the 3rd quarter valued at $83,681,000. Mawer Investment Management Ltd. lifted its holdings in shares of Bio-Rad Laboratories by 63.0% during the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after acquiring an additional 84,237 shares during the last quarter. Finally, Fisher Asset Management LLC grew its position in Bio-Rad Laboratories by 15.2% in the fourth quarter. Fisher Asset Management LLC now owns 106,871 shares of the medical research company’s stock worth $35,108,000 after acquiring an additional 14,135 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BIO shares. Royal Bank of Canada restated an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Wells Fargo & Company cut their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Stock Down 2.1 %

Shares of NYSE BIO opened at $251.16 on Wednesday. The firm has a fifty day simple moving average of $323.99 and a two-hundred day simple moving average of $331.64. Bio-Rad Laboratories, Inc. has a 12 month low of $248.22 and a 12 month high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $7.04 billion, a PE ratio of -3.86 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.